Praxis Precision Medicines stopped its Phase 2/3 EMBOLD trial early after an interim analysis showed statistically robust efficacy for relutrigine in a rare epilepsy indication. The company said the data support regulatory discussions and potential filing strategy as it prepares for next steps with the FDA. Investors reacted immediately, sending Praxis shares sharply higher. The readout could accelerate a regulatory path if final analyses confirm durable benefit and safety across subgroups; Praxis plans to engage regulators to define pivotal‑to‑approval requirements.